Speaker Profile
Founder & CEO, WideTrial
Biography
Jess Rabourn is a trained economist and former hedge fund manager whose second career in healthcare innovation began in 2009 when the second member of his immediate family was diagnosed with ALS. Since 2012, Jess has been a nationally recognized speaker on the regulation and design of Expanded Access programs (EAPs) to marry clinical research with clinical care. He produced and directed the Expanded Access Summit series of conferences in Washington DC from 2017 through 2020, and he has served on the advisory committees of several governmental, non-profit and commercial drug develop initiatives aimed at structured learning from patients' experiences. In 2018, Jess founded WideTrial, a technology and service platform to conduct large-size, data-generating EAPs across a growing network of provider sites.
Talk
Biomarker Discovery from Expanded Access Trials
Large-cohort Expanded Access Programs (EAPs) are special "treatment-use" clinical trials intended to be inclusive of broader phenotypic ranges of patients in comparison to traditional trials. Their breadth and size provide a unique opportunity to identify new biomarkers, including disease progression markers and covariates of treatment response.
Clinical & Research Tools Showcase:
WideTrial
For serious unsolved diseases, WideTrial has built a healthcare technology platform that makes it easy for physicians to bring investigational medicines to their patients. WideTrial's goal is to marry clinical care and clinical research through AI-driven therapeutic matching and a network of participating providers.
Session Abstract – PMWC 2026 Silicon Valley
The PMWC 2026 Clinical & Research Tools Showcase will provide a 15-30 minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.
